Table 4.

Net Cost Savings Projected to the National Level

						Total costs
Age (years)	Co-testing	HPV primary	Net differencea	Female U.S. population	Population distribution	Co-testing	HPV primary	Lifetime cost savingsb
30–34	$2,326	$2,365	−$39	9,965,599	13%	$23,179,983,274	$23,568,641,635	−$388,658,361
35–39	$2,298	$2,370	−$72	10,137,620	13%	$23,296,250,760	$24,026,159,400	−$729,908,640
40–44	$2,130	$2,207	−$77	10,496,987	13%	$22,358,582,310	$23,166,850,309	−$808,267,999
45–49	$1,917	$1,991	−$74	11,499,506	15%	$22,044,553,002	$22,895,516,446	−$850,963,444
50–54	$1,688	$1,755	−$67	11,364,851	14%	$19,183,868,488	$19,945,313,505	−$761,445,017
55–59	$1,383	$1,438	−$55	10,141,157	13%	$14,025,220,131	$14,582,983,766	−$557,763,635
60–64	$1,067	$1,102	−$35	8,740,424	11%	$9,326,032,408	$9,631,947,248	−$305,914,840
65–69	$666	$672	−$6	6,582,716	8%	$4,384,088,856	$4,423,585,152	−$39,496,296
Total				78,928,860				−$4,442,418,232

^aNet difference = Co-testing – HPV primary.

^bLifetime cost savings = Total co-testing costs − Total HPV primary costs.